课题基金 / 基金详情

项目摘要

项目成果

G P CHROUSOS的其他基金

相似基金

相关文献

中文摘要
翻译
这个项目的目的是增加我们对 两者内分泌和免疫系统之间的相互作用 实验动物和人类。几种免疫系统产品,如 炎性细胞因子、肿瘤坏死因子-α、白介素1、 和白介素6(IL-6)激活下丘脑-垂体-肾上腺 (HPA)轴并通过其抑制和抑制炎症/免疫 回应。白介素6对人类特别有效,刺激 不仅ACTH和皮质醇,而且精氨酸加压素(AVP)的分泌。 IL-6会导致严重的疲劳和嗜睡。血浆白介素6是 糖皮质激素缺乏状态和运动后升高。电浆 IL-6和TNFα在白天过多的紊乱中也会升高 困倦。IL-6在感染性、炎症性和 创伤状态可能解释心绞痛综合征的发病机制 在这些状态下观察到不适当的AVP分泌。我们最近 证明促肾上腺皮质激素释放激素(CRH) 局部发炎,有深刻的促炎作用 在自分泌/旁分泌的水平上。我们称之为“免疫性”CRH。 糖皮质激素和生长抑素抑制,RU 486明显增强 炎症部位局部分泌免疫CRH。CRH是一种有效的 肥大细胞脱颗粒,一种可被抑制的现象 非肽CRH拮抗剂,专用于1型受体,称为 安塔拉明。免疫CRH存在于卵巢和子宫内膜。 可能参与排卵、黄体溶解等炎症现象, 胚泡着床和月经。类风湿患者 炎症性关节炎有缺陷的垂体-肾上腺轴反应 刺激并在其炎症中产生过量的免疫性CRH 关节。多发性硬化症患者有轻微的皮质醇增多症, 它由慢性下丘脑AVP而不是CRH维持 过度分泌。人促肾上腺皮质激素释放激素基因含有雌激素反应元件 它的启动子区域为性二型性提供了解释 自身免疫性/炎症性疾病的发病率。CRH拮抗剂可能 可用于治疗自身免疫性/炎症性疾病。这个 应激激素皮质醇和儿茶酚胺抑制白细胞介素12 和/或刺激人巨噬细胞中的白介素10,导致 体液免疫的帮助型。观察到了同样的效果 组胺和P物质。
英文摘要
The purpose of this project is to increase our understanding of the interactions between the endocrine and immune systems in both experimental animals and humans. Several immune system products, such as the inflammatory cytokines, Tumor Necrosis Factor-alpha, Interleukin-1, and Interleukin-6 (IL-6) activate the hypothalamic-pituitary-adrenal (HPA) axis and through it suppress and restrain the inflammatory/immune response. Interleukin-6 is particularly potent in humans, stimulating not only ACTH and cortisol but also arginine-vasopressin (AVP) secretion. IL-6 causes profound fatigue and somnolence. Plasma interleukin-6 is elevated in glucocorticoid deficiency states and after exercise. Plasma IL-6 and TNFalpha are also elevated in disorders of excessive daytime sleepiness. Elevations of IL-6 in infectious, inflammatory, and traumatic states may explain the pathogenesis of the Syndrome of Inappropriate AVP Secretion observed in these states. We recently demonstrated that corticotropin-releasing hormone (CRH) is produced localy at sites of inflammation and has profound pro-inflammatory effects at an autocrine/paracrine level. We have called this "immune" CRH. Glucocorticoids and somatostatin suppress, and RU 486 markedly augments local secretion of immune CRH at an inflammatory site. CRH is a potent degranulator of mast cells, a phenomenon that can be inhibited by a nonpeptide CRH antagonist, specific for type 1 receptors called antalarmin. Immune CRH was found in the ovary and endometrium where it may participate in the inflammatory phenomena of ovulation, luteolysis, blastocyst implantation, and menstuation. Patients with rheumatoid arthritis have defective pituitary-adrenal axis responses to inflammatory stimuli and produce excessive amounts of immune CRH in their inflamed joints. Patients with multiple sclerosis have mild hypercortisolism, which is sustained by chronic hypothalamic AVP rather than CRH hypersecretion. The human CRH gene contains estrogen-responsive elements it its promoter region providing an explanation for the sexual dimorphism in the incidence of autoimmune/inflammatory disease. CRH antagonists may be useful in the treatment of autommune/inflammatory diseases. The stress hormones cortisol and catecholamines suppress interleukin-12 and/or stimulate interleukin-10 in human macrophages, causing a shift of the Thelper type towards humoral immunity. The same effect is observed with histamine and substance P.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHYSIOLOGY AND PATHOPHYSIOLOGY OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
PHYSIOLOGY OF STRESS AND CLINICAL APPLICATIONS OF CORTICOTROPIN RELEASING HORMONE
PHYSIOLOGY AND PATHOPHYSIOLOGY OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
ENDOCRINE-IMMUNE INTERACTIONS
海外基金